Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
RESEARCH TOOLSreports
Collegium Pharmaceutical (COLL) Stock Price & Analysis
458 Followers
COLL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.95 - $40.95
Previous Close$32.36
Volume215.60K
Average Volume (3M)491.30K
Market Cap
$1.06B
Enterprise Value$1.37B
Total Cash (Recent Filing)$318.05M
Total Debt (Recent Filing)$629.99M
Price to Earnings (P/E)13.5
Beta0.47
Next Earnings
Aug 01, 2024EPS Estimate
$1.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.40
Shares Outstanding32,715,322
10 Day Avg. Volume626,368
30 Day Avg. Volume491,301
Standard Deviation0.16
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-3.47
Price to Sales (P/S)1.83
Price to Cash Flow (P/CF)4.20
P/FCF Ratio3.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.42
Enterprise Value/Gross Profit4.20
Enterprise Value/Ebitda4.40
Forecast
1Y Price Target
$41.50Price Target Upside28.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Collegium Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Cash GenerationCash generation through 2028 is significant, with net cash expected to eclipse market cap.
Entry PointThe CEO departure sell-off creates an attractive entry point as the company remains committed to its strategy and capital allocation priorities.
Shareholder ValueThe company is generating significant cash flow and deploying capital in a shareholder-friendly way through repurchases and debt paydown.
Bears Say
Prescription TrendsPrescriptions for the product declined by approximately 7%, suggesting reduced market penetration.
Product SalesNucynta ER/IR sales dropped by about 8%, reflecting challenges in maintaining sales momentum.
Sales PerformanceXtampza ER sales declined by 4%, indicating weaker demand.
---
Ownership Overview
26.00% Insiders
36.46% Mutual Funds
36.44% Other Institutional Investors
1.10% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
COLL FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was $20.95 and its highest was $40.95 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Currently, no data Available
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on May 09, 2024. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.47 by -$0.02.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is $1.44.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 32,715,320 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of $1.45 in its last earnings report, missing expectations of $1.47. Following the earnings report the stock price went down -16.799%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Among the largest hedge funds holding Collegium Pharmaceutical’s share is Royce & Associates LLC. It holds Collegium Pharmaceutical’s shares valued at 11M.
---
Collegium Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.50 (28.24% Upside)
$41.50 (28.24% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 245.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 6.2%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.91%
12-Months-Change
Fundamentals
Return on Equity
46.43%
Trailing 12-Months
Asset Growth
-8.24%
Trailing 12-Months
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.
---
COLL Company Deck
---
COLL Earnings Call
Q1 2024
0:00 / 0:00
---
COLL Stock 12 Month Forecast
Average Price Target
$41.50
▲(28.24% Upside)
Technical Analysis
Best Analysts Covering COLL
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+22.52%
reiterated a buy rating 2 months ago
Copying Les Sulewski's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +22.52% per trade.
---